PT-141 Bremelanotide Complete Research Guide: Mechanism, Dosing, Effects & Safety 2026

PT-141, also known as bremelanotide, is a synthetic peptide analog of alpha-melanocyte stimulating hormone (α-MSH) that has gained significant attention in peptide research for its profound effects on sexual function in both men and women. Originally developed as a tanning agent (a derivative of Melanotan 2), PT-141 was later found to have potent sexual arousal effects with reduced tanning activity. This comprehensive guide covers the science behind PT-141, its mechanism of action, research dosing protocols, documented effects, side effect profiles, clinical trial data, and current research applications worldwide.

1. What is PT-141 (Bremelanotide)?

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide with the amino acid sequence Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, structurally related to Melanotan 2 but with key modifications that reduce MC1 receptor activity (tanning) while preserving MC4 receptor activity (sexual function). Its molecular weight is 1025.2 g/mol.

Development history: Developed by Palatin Technologies as a selective melanocortin receptor agonist; underwent extensive clinical trials for female sexual interest/arousal disorder (FSIAD) and erectile dysfunction (ED)
FDA approval: In June 2019, bremelanotide (brand name Vyleesi) became the first FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women, administered as an auto-injector
Key difference from Melanotan 2: PT-141 has reduced MC1 receptor affinity (less tanning) but preserved/ enhanced MC4 receptor activity (sexual function), making it more targeted for sexual health research
Receptor affinity: Agonist at MC1-R (reduced vs MT2), MC3-R, MC4-R (high affinity), and MC5-R
Half-life: Approximately 1-2 hours subcutaneous, with therapeutic effects lasting 8-24 hours

2. Mechanism of Action

Sexual Arousal (MC4 Receptor – Primary Pathway)

PT-141 crosses the blood-brain barrier and binds to MC4 receptors in the hypothalamus, specifically in the paraventricular nucleus (PVN) and medial preoptic area (MPOA)
MC4 receptor activation modulates dopamine and oxytocin signaling pathways involved in sexual motivation and arousal
Increases nitric oxide (NO) production in penile/clitoral tissue, supporting vasodilation and engorgement
Unlike PDE5 inhibitors (sildenafil, tadalafil) which work peripherally on blood flow, PT-141 works centrally on sexual desire and motivation — addressing the “brain” aspect of sexual function
Key advantage: Effective in patients who do not respond to PDE5 inhibitors, including those with psychological/neurological causes of sexual dysfunction

Skin Pigmentation (MC1 Receptor – Reduced)

PT-141 retains some MC1 receptor activity, so mild tanning can occur at higher doses
However, tanning effect is significantly reduced compared to Melanotan 2 due to structural modifications
Most research subjects report minimal to no skin darkening at standard sexual function doses

Appetite & Energy (MC4 Receptor)

MC4 receptor activation in the hypothalamus can suppress appetite
Some research subjects report mild appetite reduction, though less pronounced than with GLP-1 agonists
Increased energy and alertness are also reported in some users

3. Research Dosing Protocols

Female Sexual Dysfunction Research

Protocol	Dose	Timing	Frequency
FDA-approved (Vyleesi)	1.75 mg	45 minutes before sexual activity	As needed, max 1 dose/24h, 8 doses/month
Research starting dose	0.5-1.0 mg	2-4 hours before desired effect	2-3 times per week
Standard research dose	1.0-1.75 mg	2-4 hours before desired effect	2-3 times per week

Male Erectile Dysfunction Research

Starting dose: 0.5-1.0 mg, 2-4 hours before sexual activity
Standard dose: 1.0-1.75 mg, 2-4 hours before sexual activity
Frequency: 2-3 times per week, not exceeding one dose in 24 hours
Combination with PDE5 inhibitors: Some research explores PT-141 + sildenafil/tadalafil combinations for refractory ED (central + peripheral action); always research interactions before combining

Chronic/Low-Dose Research

Microdose protocol: 0.25-0.5 mg, 2-3 times per week, for ongoing libido support without acute effects
Loading phase: Some protocols use daily 0.5 mg for 5-7 days to build up receptor sensitivity, then maintenance dosing

Reconstitution guide: PT-141 is typically supplied in 10mg vials. Add 2ml bacteriostatic water for 5mg/ml concentration, or 5ml for 2mg/ml. For detailed instructions, see our Peptide Reconstitution Guide.

4. Clinical Trial Data & Documented Effects

Phase 3 Clinical Trials (RECONNECT Program)

The RECONNECT program consisted of two identical 24-week Phase 3 trials (NCT02333071, NCT02338960) evaluating bremelanotide in 1,247 premenopausal women with HSDD:

Primary endpoint: Change in desire (Female Sexual Function Index desire domain) and distress (Female Sexual Distress Scale)
Results: Bremelanotide 1.75 mg significantly improved desire (p<0.0001) and reduced distress (p<0.0001) compared to placebo
Responder rate: 25% of bremelanotide users reported meaningful improvement vs 17% placebo (a statistically significant 8% absolute increase)
Onset: Effects observed as early as 4 weeks, with continued improvement through 24 weeks

Male Erectile Dysfunction Research

Phase 2 trials: Bremelanotide showed efficacy in men with ED, including those who failed PDE5 inhibitor therapy
Combination therapy: Research suggests PT-141 + PDE5 inhibitor may benefit men with refractory ED by addressing both central (desire) and peripheral (blood flow) mechanisms
Key finding: PT-141 works in ED patients with psychological/neurological causes where PDE5 inhibitors are less effective

Summary of Documented Effects

Effect	Evidence Level	Notes
Increased sexual desire (women)	Strong — FDA-approved	25% responder rate in Phase 3 trials
Reduced sexual distress (women)	Strong — FDA-approved	Significant reduction in FSDS scores
Improved erectile function (men)	Moderate-Strong	Effective in PDE5-refractory ED
Increased libido (men)	Moderate	Reported across research settings
Enhanced arousal/sensation	Moderate	Reported by both sexes
Mild appetite suppression	Moderate	MC4 receptor effect
Mild tanning (high doses)	Moderate	Reduced vs Melanotan 2

5. Side Effects & Safety Profile

Common Side Effects (Clinical Trial Data)

In the Phase 3 RECONNECT trials, the most common adverse events with bremelanotide 1.75 mg were:

Nausea: 40.0% (most common; typically mild-moderate, occurs 1-2 hours post-injection, resolves within 4-8 hours; 0.6% discontinued due to nausea)
Flushing: 20.3% (facial/body warmth and redness; transient)
Injection site reactions: 13.3% (mild pain, redness, or bruising at injection site)
Headache: 11.3% (mild-moderate; usually resolves within hours)
Vomiting: 4.8% (more common at higher doses; reduced by slower titration)
Cough: 3.3% (transient, occurs shortly after injection)
Fatigue: 2.7% (mild, usually resolves within 24 hours)
Dizziness: 2.5% (mild; avoid rapid position changes after injection)

Less Common but Important Side Effects

Blood pressure changes: Transient increases in systolic blood pressure (average +1-3 mmHg) observed in clinical trials; usually resolves within 12 hours
Heart rate changes: Mild tachycardia reported in some users
Spontaneous erections/arousal: In males, can occur unexpectedly after injection; usually subsides within 4-8 hours
Skin darkening: Mild tanning possible at higher doses due to residual MC1 activity; less than Melanotan 2
Hypersensitivity reactions: Rare; discontinue if severe allergic reaction occurs

Safety Considerations & Contraindications

Cardiovascular disease: Use with caution in subjects with uncontrolled hypertension or cardiovascular disease due to transient blood pressure effects
Pregnancy/nursing: Contraindicated; no safety data in pregnancy. FDA label states “not for use in postmenopausal women or men”
Renal/hepatic impairment: Limited data; use with caution and monitor function
Melanoma/skin cancer history: Use with caution due to residual MC1 receptor activity; regular skin checks recommended
Max dosing: FDA label recommends maximum 1 dose in 24 hours and no more than 8 doses per month
Quality verification: Only use peptides with batch COAs and verified purity

6. PT-141 vs Melanotan 2 vs Other Compounds

Compound	MC1 (Tanning)	MC4 (Sexual)	Primary Use	Nausea Risk
PT-141 (Bremelanotide)	Low-Moderate	Very High	Sexual function	High (40%)
Melanotan 2	Very High	High	Tanning + sexual	Moderate-High
Melanotan I	High	Minimal	Tanning only	Low-Moderate
Sildenafil (Viagra)	None	None (peripheral)	ED (blood flow)	Low
Flibanserin (Addyi)	None	None (5-HT)	Low desire (women)	Moderate

For detailed comparison, see our Melanotan 2 vs PT-141 Comparison Guide.

7. Global Research & Regulatory Status

United States: Bremelanotide (Vyleesi) is FDA-approved for HSDD in premenopausal women (June 2019). Research-grade PT-141 is legally available for laboratory research with proper labeling. Not approved for male use by FDA.
United Kingdom: Not licensed by the MHRA for any indication. Legal for research purposes. Can be prescribed off-label by private clinicians in some cases.
Australia: Not included in the ARTG. The TGA regulates therapeutic goods; research-only compounds are exempt when properly labeled. Off-label prescribing may be possible via Authorized Prescriber pathway.
Canada: Not approved by Health Canada. Legal for laboratory research. Health Canada has not issued specific warnings for PT-141 research compounds.
Europe: Not approved by the EMA as of 2026 (EMA review was discontinued in 2020). Legal status varies by country; research use is generally permitted.

8. Frequently Asked Questions

How long does PT-141 take to work? Onset of effects is typically 1-4 hours after subcutaneous injection, with peak effects at 2-4 hours. The FDA-approved Vyleesi auto-injector is administered 45 minutes before anticipated sexual activity. Effects can last 8-24 hours.

How is PT-141 different from Viagra (sildenafil)? This is the most important distinction: Viagra works peripherally by increasing blood flow to the penis (PDE5 inhibition), but does not increase sexual desire. PT-141 works centrally in the brain by activating MC4 receptors that increase sexual desire and motivation. PT-141 is effective in patients who do not respond to Viagra, including those with psychological or neurological causes of ED. Some research explores combining both for maximum effect.

Is PT-141 safe for long-term use? Clinical trials have evaluated up to 24 weeks of use with no serious long-term safety signals identified. The most common side effects (nausea, flushing) are transient and tend to decrease with continued use. Long-term safety beyond 24 weeks is still being studied. Research subjects should use cycling protocols and monitor blood pressure.

Can men use PT-141? While FDA approval is specifically for premenopausal women with HSDD, PT-141 has been extensively researched in men with erectile dysfunction. Phase 2 trials showed efficacy in male ED, including patients who failed PDE5 inhibitor therapy. Research-grade PT-141 is used by male researchers worldwide, though it is not FDA-approved for male use.

What is the best injection site for PT-141? Subcutaneous injection into abdominal fat is most common and well-absorbed. The FDA-approved Vyleesi auto-injector is administered to the abdomen or thigh. Rotate injection sites to prevent lipodystrophy. Intranasal administration has been studied but is less reliable and not the standard route.

Does PT-141 cause tanning? PT-141 has reduced MC1 receptor affinity compared to Melanotan 2, so tanning is significantly diminished. At standard sexual function doses (1.0-1.75 mg), most research subjects report minimal to no skin darkening. Mild tanning can occur at higher doses or with frequent use, but it is much less pronounced than with Melanotan 2.

How should I store PT-141? Lyophilized powder should be stored in a cool, dry place away from direct light (refrigerator at 2-8°C preferred for long-term storage). After reconstitution with bacteriostatic water, store in the refrigerator and use within 30 days. Do not freeze reconstituted solution. See our Peptide Storage Guide.

European Country-Specific Buying Guides

Shop High-Purity PT-141 for Research

Hanpro Peptides supplies research-grade PT-141 (Bremelanotide) with verified 99%+ purity, batch-specific Certificates of Analysis, and worldwide shipping. Browse our PT-141 and related sexual health compounds including Melanotan 2 and Kisspeptin. Every batch is tested by HPLC and mass spectrometry. We accept credit cards, PayPal, and cryptocurrency for researchers worldwide.

Disclaimer: This article is for educational and research purposes only. PT-141 (bremelanotide) is a research compound. While Vyleesi is FDA-approved for HSDD in premenopausal women, research-grade PT-141 is not approved for human use outside of approved clinical settings. Research use requires proper ethical review and should only be conducted in approved laboratory settings. This article does not constitute medical advice. Always consult qualified researchers and medical professionals regarding research protocols and safety considerations.

Guías Regionales / Regional Guides

América Latina / Latin America:

Asia / 亚洲:

Middle East / الشرق الأوسط:

شراء الببتيدات البحثية في الإمارات العربية المتحدة: دليل شامل

Africa / أفريقيا:

Buying Research Peptides in South Africa: Complete Guide

🌍 更多地区研究肽类购买指南

探索我们为全球研究人员准备的地区专属指南：

🇫🇷 法语地区

Achat de peptides de recherche en Côte d’Ivoire

Uncategorized

PT-141 Bremelanotide Complete Research Guide: Mechanism, Dosing, Effects & Safety 2026